Drug Class: Hormonal Therapy

GR Antagonists

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

2.5 Prior Therapies 3 Prior Therapies

GR Antagonists

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT03776812 II nab-Paclitaxel, Relacorilant A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Intermittent relacorilant+nab-paclitaxel improves PFS and DoR and has a favorable safety profile in recurrent platinum resistant and/or platinum refractory ovarian cancer patients

Continuous Rel+Nab vs Intermittent Rel+Nab vs Nab:

ORR: 35.2 vs 35.7 vs 35.8%
PFS: 5.29 vs 5.55* vs 3.76 months
DoR: 3.79 vs 5.55* vs 3.65 months

abs Sept 2021

*Statistically significant result

< Return to Drug Classes

< Return to Clinical Trial Results Homepage